2‐Hydroxyl hispolon reverses high glucose‐induced endothelial progenitor cell dysfunction through the PI3K/Akt/eNOS and AMPK/HO‐1 pathways
This article is part of a themed issue Recent Innovations in Targeting Redox Biology for Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.1/issuetoc.
Authors
- Ta‐Jung Wang (ORCID: https://orcid.org/0000-0002-0124-9524)
- Ju‐Chi Liu (ORCID: https://orcid.org/0000-0001-6615-3200)
- Bu‐Yuan Hsiao (ORCID: https://orcid.org/0009-0000-7822-5937)
- Yu‐Tsung Shih (ORCID: https://orcid.org/0000-0002-5277-533X)
- Wen‐Chi Hou (ORCID: https://orcid.org/0000-0002-9565-7018)
- Y. J. Chen (ORCID: https://orcid.org/0000-0003-3948-0753)
- Chan Yang (ORCID: https://orcid.org/0000-0002-6727-8790)
- T.N. Lo
Institutions
- Taipei Medical University Hospital (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1111/bph.70002
- Citations
- 3
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42